Skip to main content
Premium Trial:

Request an Annual Quote

Precision Therapeutics CLIA-Certified to Offer Med BioGene's GeneFx Lung Assay

NEW YORK (GenomeWeb News) – Med BioGene today said that its commercial partner, Precision Therapeutics, has been certified to perform Med BioGene's lung cancer test out of Precision's Pittsburgh laboratory.

The test, called GeneFx Lung, is a gene expression test for identifying patients with early stage non-small cell lung cancer who, after surgical removal of their tumor, are at higher or lower risks for mortality. Med BioGene and Precision reached a licensing agreement for the test, previously called LungExpress Dx, in 2011.

Med BioGene, based in Vancouver, British Columbia, said that Precision will have discussions with payors "to better understand the current landscape and the specific needs of relevant payors as they apply to GeneFx Lung." The timing of the launch will be determined based on the discussions.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.